Abbott Park, Illinois — Abbott today announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by ...

Two-Year Data on Abbott's Investigational MitraClip® System to be Highlighted as a Late-Breaking Clinical Trial on April 4 One-Year Data on the ABSORB™ Bioresorbable Vascular Scaffold to be Presented ...

Editor’s Note: This article originally appeared on Abbott’s website. Abbott announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...

Now available for use with both Apple and Android devices, the app helps people track pain relief during the treatment journey with neurostimulation devices Updated app provides doctors with an ...

ABBOTT PARK, Ill., Nov. 1, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced 'Countdown at a Crossroads,' which kicks off National Diabetes Awareness Month by taking over the Oculus Center in ...

Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

CERRITOS, Calif.—R.D. Abbott Co. Inc. and Alpha Technologies are joining forces to present a one-day course on rheology applications Feb. 10 at R.D. Abbott's headquarters in Cerritos. The cost of the ...

Abbott and Shepherd aim to raise awareness of the rising rates of diabetes diagnoses and how access to continuous glucose monitoring (CGM) systems can reduce diabetes-related complications 1, provide ...